Wu MS 2007.

Methods	Country: China Setting: outpatients and inpatients Aim: to study the effects of prescription for tonifying kidney in the treatment of osteoporosis Study design: randomised controlled trial Analysis: T‐test, Ridit test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 180 osteoporosis patients enrolled: 30 in prescription for tonifying kidney group, 30 in kidney meridian sticking group, 30 in urinary bladder meridian sticking group, 30 in ipriflavone group, 30 in Gushukang group, 30 in non‐meridian or acupoint sticking group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis, patients with fractures, etc.
Interventions	Experimental: prescription for tonifying kidney, 10 pills, 3 times a day; Kanggusong Tieji (kidney meridian sticking or urinary bladder meridian sticking), once per 2 days; for 6 months Control: ipriflavone, 200 mg, 3 times a day, for 6 months
Outcomes	BMD, Ca, P, E2, PTH, CT, adverse effects
Notes	The study was supported by the National Natural Science Foundation, but no declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias